Company intelligence / Profile preview
Isarna Therapeutics
Munich, Bavaria, Germanyisarna-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company's lead compound ISTH0036 is in Phase 2a clinical development for ophthalmic conditions. The BETTER study has reported a good safety profile for ISTH0036 and efficacy in wet AMD and DME patients. The study is investigating reduction of retinal fluid and central macular thickness as primary endpoints, and improvement of visual acuity as a secondary endpoint[2].
- Therapeutic areas
- OphthalmologyOncologyGastroenterologyRheumatology
- Modalities
- Antisense oligonucleotides
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Isarna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Isarna Therapeutics.